FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1915612196> ?p ?o ?g. }

• W1915612196 abstract "ABSTRACT Aim: BRAWO is a German non-interventional study of 3000 patients (pts) with advanced or metastatic, hormone-receptor-positive and HER2-negative breast cancer treated with everolimus (EVE) and exemestane (EXE). Data is collected at about 400 sites. Main objectives are to extend the knowledge on a) the impact of physical activity on efficiency and quality of life, b) prophylaxis and management of stomatitis in clinical routine, and c) the sequence of therapy, when EVE is used in daily clinical practice. We report the results of the 2nd preplanned interim analysis (IA) which was defined to take place 12 months after the inclusion of the 500th patient into the documentation. Methods: The 2nd interim analysis (data cut-off 08 Jul 2014) covers data of the first 500 documented patients (pts) and evaluated for the first time progression free survival (PFS). Furthermore, baseline data, safety data and the tumor status were analyzed. Results: At the time of data cut-off, 409 pts had discontinued the study, 91 were still ongoing. Baseline characteristics: Median age: 66 yrs; median BMI: 25.9; ECOG 0-1: 377 (89.8%); visceral metastases: 53.7%; bone only metastases: 26.3%. 26.2% pts received EVE and EXE as first treatment (first line), 28.8% as second line, 18.8% as third line and 26.2% as fourth or later line in the advanced setting. 18.6% of pts had received EXE earlier in their treatment history. The median PFS was 8.0 months (6.7; 9.1; 95% CI). For pts receiving EVE/EXE as first treatment for the advanced setting (N = 131) median PFS was 10.1 months (6.7; 17.6). 41.6% of these 500 pts had at least one stomatitis event: 19.8 % grade 1, 15.8% grade 2 and 3.4% grade 3. 86.8% of pts received recommendations regarding stomatitis prevention from their physician. The general safety profile was consistent with previously reported safety findings. Conclusions: Here we present for the first time efficacy data on EVE/EXE under real world conditions. The data confirm the efficacy results of the pivotal phase 3 trial BOLERO-2 (median PFS vs placebo +EXE: 7.8 months vs 3.2 months, respectively by local radiologic assessment). Disclosure: P.A. Fasching: Consulting Fees: Novartis Speakers' Bureau: Pfizer, Roche, Novartis, Genomic Health Grant/Research Support: Novartis, Amgen; T. Decker: Consulting Fees: Novartis PI/Lead investigator: Novartis; A. Schneeweiss: Consulting Fees: Roche, Celgene, Novartis Honoraria: Astra, Roche, Celgene, Eisai, Medac, GlaxoSmithKline, Pfizer; C. Uleer: Consulting Fees: Novartis Honoraria: Novartis, Roche, AstraZeneca, Amgen; P. Wimberger: Honoraria scientific lectures Novartis; C.M. Kurbacher: Consulting Fees: CFL Contracted Research: Amgen, Novartis, Hexal, Roche, Teva Honoraria: Teva, Amgen; N. Harbeck, W. Bloch, H. Tesch and F. Schutz: Consulting Fees: Novartis Honoraria: Novartis; S. Kummel: Consulting Fees: Roche; M. Muth and J. Kreuzeder: Employee of Novartis Pharma GmbH, Germany; D. Luftner: Consulting Fees: Novartis Contracted Research: Novartis Honoraria: Novartis; C. Jackisch: Consulting Fees: Novartis. All other authors have declared no conflicts of interest." @default.
• W1915612196 created "2016-06-24" @default.
• W1915612196 creator A5004071807 @default.
• W1915612196 creator A5011268087 @default.
• W1915612196 creator A5013148496 @default.
• W1915612196 creator A5014400962 @default.
• W1915612196 creator A5016987068 @default.
• W1915612196 creator A5017728105 @default.
• W1915612196 creator A5020142852 @default.
• W1915612196 creator A5024973148 @default.
• W1915612196 creator A5027231412 @default.
• W1915612196 creator A5029656956 @default.
• W1915612196 creator A5035775338 @default.
• W1915612196 creator A5035799597 @default.
• W1915612196 creator A5040767616 @default.
• W1915612196 creator A5050467390 @default.
• W1915612196 creator A5069170386 @default.
• W1915612196 creator A5071893291 @default.
• W1915612196 creator A5072762948 @default.
• W1915612196 creator A5080841059 @default.
• W1915612196 creator A5089392438 @default.
• W1915612196 creator A5024366310 @default.
• W1915612196 date "2014-09-01" @default.
• W1915612196 modified "2023-10-09" @default.
• W1915612196 title "Breast Cancer Treatment with Everolimus and Exemestane for Er+ Women - Results of the 2Nd Interim Analysis of the Non-Interventional Trial Brawo" @default.
• W1915612196 doi "https://doi.org/10.1093/annonc/mdu438.6" @default.
• W1915612196 hasPublicationYear "2014" @default.
• W1915612196 type Work @default.
• W1915612196 sameAs 1915612196 @default.
• W1915612196 citedByCount "7" @default.
• W1915612196 countsByYear W19156121962015 @default.
• W1915612196 countsByYear W19156121962016 @default.
• W1915612196 countsByYear W19156121962018 @default.
• W1915612196 countsByYear W19156121962020 @default.
• W1915612196 countsByYear W19156121962021 @default.
• W1915612196 crossrefType "journal-article" @default.
• W1915612196 hasAuthorship W1915612196A5004071807 @default.
• W1915612196 hasAuthorship W1915612196A5011268087 @default.
• W1915612196 hasAuthorship W1915612196A5013148496 @default.
• W1915612196 hasAuthorship W1915612196A5014400962 @default.
• W1915612196 hasAuthorship W1915612196A5016987068 @default.
• W1915612196 hasAuthorship W1915612196A5017728105 @default.
• W1915612196 hasAuthorship W1915612196A5020142852 @default.
• W1915612196 hasAuthorship W1915612196A5024366310 @default.
• W1915612196 hasAuthorship W1915612196A5024973148 @default.
• W1915612196 hasAuthorship W1915612196A5027231412 @default.
• W1915612196 hasAuthorship W1915612196A5029656956 @default.
• W1915612196 hasAuthorship W1915612196A5035775338 @default.
• W1915612196 hasAuthorship W1915612196A5035799597 @default.
• W1915612196 hasAuthorship W1915612196A5040767616 @default.
• W1915612196 hasAuthorship W1915612196A5050467390 @default.
• W1915612196 hasAuthorship W1915612196A5069170386 @default.
• W1915612196 hasAuthorship W1915612196A5071893291 @default.
• W1915612196 hasAuthorship W1915612196A5072762948 @default.
• W1915612196 hasAuthorship W1915612196A5080841059 @default.
• W1915612196 hasAuthorship W1915612196A5089392438 @default.
• W1915612196 hasBestOaLocation W19156121961 @default.
• W1915612196 hasConcept C121608353 @default.
• W1915612196 hasConcept C126322002 @default.
• W1915612196 hasConcept C141071460 @default.
• W1915612196 hasConcept C143998085 @default.
• W1915612196 hasConcept C159110408 @default.
• W1915612196 hasConcept C160798450 @default.
• W1915612196 hasConcept C166957645 @default.
• W1915612196 hasConcept C2775860665 @default.
• W1915612196 hasConcept C2776957806 @default.
• W1915612196 hasConcept C2777176818 @default.
• W1915612196 hasConcept C2779699572 @default.
• W1915612196 hasConcept C2779951463 @default.
• W1915612196 hasConcept C530470458 @default.
• W1915612196 hasConcept C535046627 @default.
• W1915612196 hasConcept C61943457 @default.
• W1915612196 hasConcept C71924100 @default.
• W1915612196 hasConcept C95457728 @default.
• W1915612196 hasConceptScore W1915612196C121608353 @default.
• W1915612196 hasConceptScore W1915612196C126322002 @default.
• W1915612196 hasConceptScore W1915612196C141071460 @default.
• W1915612196 hasConceptScore W1915612196C143998085 @default.
• W1915612196 hasConceptScore W1915612196C159110408 @default.
• W1915612196 hasConceptScore W1915612196C160798450 @default.
• W1915612196 hasConceptScore W1915612196C166957645 @default.
• W1915612196 hasConceptScore W1915612196C2775860665 @default.
• W1915612196 hasConceptScore W1915612196C2776957806 @default.
• W1915612196 hasConceptScore W1915612196C2777176818 @default.
• W1915612196 hasConceptScore W1915612196C2779699572 @default.
• W1915612196 hasConceptScore W1915612196C2779951463 @default.
• W1915612196 hasConceptScore W1915612196C530470458 @default.
• W1915612196 hasConceptScore W1915612196C535046627 @default.
• W1915612196 hasConceptScore W1915612196C61943457 @default.
• W1915612196 hasConceptScore W1915612196C71924100 @default.
• W1915612196 hasConceptScore W1915612196C95457728 @default.
• W1915612196 hasLocation W19156121961 @default.
• W1915612196 hasOpenAccess W1915612196 @default.
• W1915612196 hasPrimaryLocation W19156121961 @default.
• W1915612196 hasRelatedWork W2031131661 @default.
• W1915612196 hasRelatedWork W2113458582 @default.
• W1915612196 hasRelatedWork W2167188058 @default.
• W1915612196 hasRelatedWork W2520458330 @default.
• W1915612196 hasRelatedWork W2570918630 @default.
• W1915612196 hasRelatedWork W2586466848 @default.

• next